JP2001502299A - リポソーム - Google Patents
リポソームInfo
- Publication number
- JP2001502299A JP2001502299A JP10513398A JP51339898A JP2001502299A JP 2001502299 A JP2001502299 A JP 2001502299A JP 10513398 A JP10513398 A JP 10513398A JP 51339898 A JP51339898 A JP 51339898A JP 2001502299 A JP2001502299 A JP 2001502299A
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- polynucleotide
- liposomes
- dna
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.リポソーム形成成分、及びリポソーム内に取り込まれた、ヒト又は動物に所 望の免疫応答を誘導するのに有用な免疫原性ポリペブチドを機能的にコードする ポリヌクレオチドから形成されるリポソームを含有する組成物。 2.ポリヌクレオチドが、二本鎖DNAである請求項1に記載の組成物。 3.ポリヌクレオチドが、プロモーター及び必要に応じてリボソーム結合配列を 含むプラスミドの形態である請求項2に記載の組成物。 4.ポリヌクレオチドが、RNA、好ましくはmRNAである請求項1に記載の 組成物。 5.免疫原性のポリペプチドが、感染性微生物の抗原若しくは抗原のフラグメン トを含有する前記いずれかの請求項に記載の組成物。 6.リポソーム形成成分が、リポソームが全体として電 荷を有さないように選択された前記いずれかの請求項に記載の組成物。 7.リポソーム形成成分が、少なくとも1種のカチオンに荷電したリポソーム形 成成分を、リポソーム形成成分が全体としてカチオンに電荷を有する量で含有す る請求項1〜5のいずれかに記載の組成物。 8.少なくとも1種のカチオン性荷電成分をリポソーム形成成分が全体として正 の電荷を有する量で、並びに所望のポリペプチド生成物をコードするポリヌクレ オチドを含有する成分から形成されるリポソームであって、該リポソーム内に上 記ポリヌクレオチドが取り込まれていることを特徴とするリポソームを含有する 組成物。 9.カチオン性成分が、一般式 [式中、Y1及びY2は、同一又は異なって、−O−又はO−C(O)−であり、 この場合カルボニル炭素は、場 合により、R2又はR1に結合する;R1及びR2はそれぞれ独立して炭素数6〜2 4のアルキル基、アルケニル基、又はアルキニル基であり、R3、R4及びR5は 、それぞれ独立して、水素、炭素数1〜8のアルキル、炭素数6〜11のアリー ル又はアラルキルであり;或いは、R3、R4及びR5の2又は3個は正電荷を有 する窒素原子と結合して原子数5〜8の環状構造を形成し、この場合、正電荷を 有する窒素原子に加えて、この構造中の原子は炭素原子であり、一個の酸素、窒 素又は硫黄原子を含むことができる;nは1〜8であり;Xはアニオンである。 ] を有するグリセリド又はその光学異性体である請求項7又は8に記載の組成物。 10.R1及びR2が各々0〜6の不飽和部分を有し、構造 CH3−(CH2)a−(CH=CH−CH2)b−(CH2)c− [式中、aとcの合計は1〜23であり;bは0〜6である。] を有する請求項9に記載の組成物。 11.カチオン性成分が、DOTAP、BisHOP、DC−Chol及びステアリルアミンから 選ばれるものである請求項7又は 8に記載の組成物。 12.リポソーム形成成分が、融合誘導性成分、好ましくはホスファチジルエタ ノールアミンを含む前記いずれかの請求項に記載の組成物。 13.リポソームが、脱水−再水和工程、好ましくは次いで微小流動化工程又は 押出を行うことにより形成されるものである前記いずれかの請求項に記載の組成 物。 14.リポソームの平均直径が、100〜1000nm、好ましくは200〜5 00nmである前記いずれかの請求項に記載の組成物。 15.リポソーム形成成分mg当たり0.1〜10μgのポリヌクレオチドを含 有する前記いずれかの請求項に記載の組成物。 16.ヒト又は動物を治療又は予防処置する方法に用いる組成物の製造のための 前記いずれかの請求項に規定されたリポソームの使用。 17.上記方法が、感染性微生物又はガン細胞に対する免疫化のためのワクチン 接種である請求項16に記載の使用。 18.組成物を筋肉内投与する請求項16又は17記載の使用。 19.請求項1〜15のいずれかに記載のリポソーム調製物及び薬学的に許容さ れる賦形剤を含有する薬学的組成物。 20.請求項19に記載の薬学的組成物をヒト又は動物に投与し、それによって 標的細胞においてポリヌクレオチドのポリペプチド生成物が発現される、かかる 処置を必要とするヒト又は動物の処置方法。 21.薬学的組成物を筋肉内投与する請求項20に記載の方法。 22.薬学的組成物を皮下投与する請求項20に記載の方法。 23.薬学的組成物を静脈内投与する請求項20に記載の方法。 24.薬学的組成物を腹腔内投与する請求項20に記載の方法。 25.細胞を請求項1〜15のいずれかに記載のリポソーム組成物と接触させ、 該細胞を培養し、それにより細胞のトランスフェクション及びポリヌクレオチド の発現並びにポリヌクレオチドのポリペプチド生成物の合成が起こる、ヒト又は 動物から単離した細胞のトランスフェクション方法。 26.次いで培養細胞を宿主動物又はヒトに移植し、ポリペブチドの発現がin v ivoで生じる請求項25に記載の方法。 27.発現されたポリヌクレオチドが所望の免疫応答、好ましくは感染性微生物 又はガン細胞の抗原に対する応答を誘導する請求項20〜24のいずれかに記載 の方法。 28.1.ヒト又は動物において所望の免疫応答を誘導す るのに有用な免疫原性ポリペプチドを機能的にコードする裸のポリヌクレオチド 及び予め形成されたリポソームを含有する水性懸濁液を形成し、 2.該懸濁液を凍結乾燥し、 3.工程2の生成物を再水和し、 4.工程3の脱水、再水和された小胞の水性懸濁液を微小流動化に供し、 5.必要に応じて、取り込まれなかったポリヌクレオチドをリポソームか ら分離する 工程を含むポリヌクレオチドをリポソーム内に取り込む方法。 29.リポソームがカチオン性リポソームである請求項28に記載の方法。 30.1.裸のポリヌクレオチド及び予め形成されたカチオン性リポソームを含有 する水性懸濁液を形成し、 2.該懸濁液を凍結乾燥し、 3.工程2の生成物を再水和し、 4.工程3の脱水、再水和された小胞の水性懸濁液を微小流動化に供し、 5.必要に応じて、取り込まれなかったポリヌクレ オチドをリポソームから分離する 工程を含むポリヌクレオチドをリポソーム内に取り込む方法。 31.工程1〜4におけるポリヌクレオチドの取り込み率が、工程1の懸濁液中 のポリヌクレオチドの10〜90%、好ましくは20〜85%の範囲である請求 項28〜30のいずれかに記載の方法。 32.最終生成物における、ポリヌクレオチドの濃度が、リポソーム形成成分m gあたり0.1〜20μgである請求項28〜31のいずれかに記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619172.1A GB9619172D0 (en) | 1996-09-13 | 1996-09-13 | Liposomes |
GB9619172.1 | 1996-09-13 | ||
GBGB9625917.1A GB9625917D0 (en) | 1996-12-13 | 1996-12-13 | Liposomes |
GB9625917.1 | 1996-12-13 | ||
GBGB9713994.3A GB9713994D0 (en) | 1997-07-01 | 1997-07-01 | Liposomes |
GB9713994.3 | 1997-07-01 | ||
PCT/GB1997/002490 WO1998010748A1 (en) | 1996-09-13 | 1997-09-15 | Liposomes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001502299A true JP2001502299A (ja) | 2001-02-20 |
JP2001502299A5 JP2001502299A5 (ja) | 2005-09-08 |
Family
ID=27268476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10513398A Ceased JP2001502299A (ja) | 1996-09-13 | 1997-09-15 | リポソーム |
Country Status (11)
Country | Link |
---|---|
US (1) | US7790696B2 (ja) |
EP (2) | EP1254657B1 (ja) |
JP (1) | JP2001502299A (ja) |
KR (1) | KR100507660B1 (ja) |
CN (1) | CN1138533C (ja) |
AT (2) | ATE395904T1 (ja) |
AU (1) | AU728581B2 (ja) |
CA (1) | CA2271388C (ja) |
DE (2) | DE69738719D1 (ja) |
ES (2) | ES2187812T3 (ja) |
WO (1) | WO1998010748A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004525898A (ja) * | 2001-02-21 | 2004-08-26 | ノヴォソム アクチェンゲゼルシャフト | 両性リポソーム及びその使用 |
JP2005245342A (ja) * | 2004-03-05 | 2005-09-15 | Mitsubishi Kagaku Bio-Clinical Laboratories Inc | 細胞中atpの定量法 |
JP2012532200A (ja) * | 2009-07-06 | 2012-12-13 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
JP2015520195A (ja) * | 2012-06-08 | 2015-07-16 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536344A (ja) * | 1999-02-05 | 2002-10-29 | ジエンザイム コーポレイション | 抗腫瘍免疫を発生させるためのカチオン性脂質の使用 |
EP1217989B1 (en) * | 1999-10-01 | 2005-12-14 | Lipoxen Technologies Limited | Vaccines for oral use which contain liposome-entrapped dna |
ATE274901T1 (de) | 1999-12-13 | 2004-09-15 | Lipoxen Technologies Ltd | Liposomen enthaltend einen komplex aus polyanion und calciumphosphat |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
EP1519745B1 (en) * | 2002-07-05 | 2006-12-20 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
CN100400667C (zh) * | 2006-06-27 | 2008-07-09 | 浙江大学 | 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途 |
WO2008077413A1 (es) | 2006-12-22 | 2008-07-03 | Soluciones Biotecnologicas Innovacion Ltda | Vacunas adn en peces |
EP2184054A1 (en) | 2008-11-08 | 2010-05-12 | Lipoxen Technologies Limited | Small Interfering RNA Delivery |
WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US10525152B2 (en) | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
NZ600616A (en) | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
CN102884041B (zh) * | 2010-04-28 | 2015-04-15 | 协和发酵麒麟株式会社 | 阳离子性脂质 |
SI4005592T1 (sl) | 2010-07-06 | 2023-03-31 | Glaxosmithkline Biologicals S.A. | Virionom podobni dostavni delci za samopodvojene molekule RNA |
SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
WO2012006367A2 (en) | 2010-07-06 | 2012-01-12 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
WO2012006380A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Cationic oil-in-water emulsions |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
ES2716243T3 (es) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
CN103501811B (zh) | 2011-01-13 | 2016-03-30 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
RU2491062C2 (ru) * | 2011-03-16 | 2013-08-27 | Общество С Ограниченной Ответственностью "Биотехнологии Пущино" | Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий |
CN105999250B (zh) | 2011-05-24 | 2020-03-10 | 生物技术Rna制药有限公司 | 用于癌症的个体化疫苗 |
KR102128248B1 (ko) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
JP6120839B2 (ja) | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
WO2013006834A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
RU2698906C2 (ru) | 2012-01-27 | 2019-09-02 | Вэриэйшн Биотекнолоджиз, Инк. | Способы и композиции для терапевтических агентов |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
DK2968586T3 (en) | 2013-03-14 | 2018-10-08 | Translate Bio Inc | CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2015061500A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
US20160324986A1 (en) * | 2013-12-27 | 2016-11-10 | Teloregen, Inc. | Compositions and methods for providing active telomerase to cells in vivo |
WO2015107140A1 (en) * | 2014-01-17 | 2015-07-23 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | Liposome-based immunotherapy |
JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの精製方法 |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
AU2022245985A1 (en) | 2021-03-22 | 2023-09-21 | Illumina Cambridge Limited | Methods for improving nucleic acid cluster clonality |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6447381A (en) * | 1987-08-19 | 1989-02-21 | Vitamin Kenkyusho Kk | Preparation of liposome containing sealed gene |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
JPH02135092A (ja) * | 1988-11-14 | 1990-05-23 | Bitamin Kenkyusho:Kk | 細胞への遺伝子導入法 |
WO1991017424A1 (en) * | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
JPH04108391A (ja) * | 1990-08-27 | 1992-04-09 | Vitamin Kenkyusho:Kk | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
WO1995004524A1 (en) * | 1993-08-06 | 1995-02-16 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
WO1996026179A1 (en) * | 1995-02-21 | 1996-08-29 | Imarx Pharmaceutical Corp. | Novel cationic lipids and the use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
DE3582905D1 (de) | 1984-08-10 | 1991-06-27 | Syntex Inc | Stabile liposome mit wasserloeslichen arzneimitteln. |
US5550289A (en) * | 1985-01-07 | 1996-08-27 | Syntex (U.S.A.) Inc. | N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor |
US5208036A (en) * | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
NZ214716A (en) | 1985-01-07 | 1989-04-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US4882172A (en) * | 1988-04-08 | 1989-11-21 | Nabisco Brands, Inc. | System for processing chewing gum |
EP1026253B2 (en) | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
EP0625049A4 (en) | 1992-01-23 | 1995-07-12 | Vical Inc | EX VIVO GENTRANSFER. |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
EP0678017B1 (en) * | 1993-11-05 | 1998-04-01 | Amgen Inc. | Liposome preparation and material encapsulation method |
KR100241300B1 (ko) * | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
ATE285477T1 (de) * | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
US5830878A (en) * | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5753235A (en) * | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
-
1997
- 1997-09-15 WO PCT/GB1997/002490 patent/WO1998010748A1/en active IP Right Grant
- 1997-09-15 DE DE69738719T patent/DE69738719D1/de not_active Expired - Lifetime
- 1997-09-15 CN CNB971996741A patent/CN1138533C/zh not_active Expired - Fee Related
- 1997-09-15 JP JP10513398A patent/JP2001502299A/ja not_active Ceased
- 1997-09-15 ES ES97940250T patent/ES2187812T3/es not_active Expired - Lifetime
- 1997-09-15 DE DE69717661T patent/DE69717661T2/de not_active Expired - Lifetime
- 1997-09-15 KR KR10-1999-7002103A patent/KR100507660B1/ko not_active IP Right Cessation
- 1997-09-15 ES ES02016936T patent/ES2305157T3/es not_active Expired - Lifetime
- 1997-09-15 AU AU42154/97A patent/AU728581B2/en not_active Ceased
- 1997-09-15 EP EP02016936A patent/EP1254657B1/en not_active Expired - Lifetime
- 1997-09-15 AT AT02016936T patent/ATE395904T1/de not_active IP Right Cessation
- 1997-09-15 EP EP97940250A patent/EP0938298B1/en not_active Expired - Lifetime
- 1997-09-15 CA CA002271388A patent/CA2271388C/en not_active Expired - Fee Related
- 1997-09-15 AT AT97940250T patent/ATE228824T1/de not_active IP Right Cessation
-
2008
- 2008-04-10 US US12/101,107 patent/US7790696B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
JPS6447381A (en) * | 1987-08-19 | 1989-02-21 | Vitamin Kenkyusho Kk | Preparation of liposome containing sealed gene |
JPH02135092A (ja) * | 1988-11-14 | 1990-05-23 | Bitamin Kenkyusho:Kk | 細胞への遺伝子導入法 |
WO1991017424A1 (en) * | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
JPH04108391A (ja) * | 1990-08-27 | 1992-04-09 | Vitamin Kenkyusho:Kk | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
WO1995004524A1 (en) * | 1993-08-06 | 1995-02-16 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
WO1996026179A1 (en) * | 1995-02-21 | 1996-08-29 | Imarx Pharmaceutical Corp. | Novel cationic lipids and the use thereof |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004525898A (ja) * | 2001-02-21 | 2004-08-26 | ノヴォソム アクチェンゲゼルシャフト | 両性リポソーム及びその使用 |
JP2014218520A (ja) * | 2001-02-21 | 2014-11-20 | マリナ バイオテック インコーポレイテッド | 両性リポソーム及びその使用 |
JP2016104786A (ja) * | 2001-02-21 | 2016-06-09 | マリナ バイオテック インコーポレイテッド | 両性リポソーム及びその使用 |
JP2005245342A (ja) * | 2004-03-05 | 2005-09-15 | Mitsubishi Kagaku Bio-Clinical Laboratories Inc | 細胞中atpの定量法 |
JP4546115B2 (ja) * | 2004-03-05 | 2010-09-15 | 三菱化学メディエンス株式会社 | 細胞中atpの定量法 |
JP2012532200A (ja) * | 2009-07-06 | 2012-12-13 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
JP2015520195A (ja) * | 2012-06-08 | 2015-07-16 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
Also Published As
Publication number | Publication date |
---|---|
CN1237102A (zh) | 1999-12-01 |
ATE395904T1 (de) | 2008-06-15 |
CA2271388A1 (en) | 1998-03-19 |
US7790696B2 (en) | 2010-09-07 |
ES2305157T3 (es) | 2008-11-01 |
EP1254657A3 (en) | 2003-03-05 |
AU4215497A (en) | 1998-04-02 |
ATE228824T1 (de) | 2002-12-15 |
DE69738719D1 (de) | 2008-07-03 |
KR100507660B1 (ko) | 2005-08-10 |
DE69717661T2 (de) | 2003-09-25 |
AU728581B2 (en) | 2001-01-11 |
EP1254657A2 (en) | 2002-11-06 |
EP0938298A1 (en) | 1999-09-01 |
CA2271388C (en) | 2007-11-06 |
EP1254657B1 (en) | 2008-05-21 |
EP0938298B1 (en) | 2002-12-04 |
WO1998010748A1 (en) | 1998-03-19 |
KR20000036088A (ko) | 2000-06-26 |
CN1138533C (zh) | 2004-02-18 |
ES2187812T3 (es) | 2003-06-16 |
DE69717661D1 (de) | 2003-01-16 |
US20080286353A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001502299A (ja) | リポソーム | |
Guevara et al. | Advances in lipid nanoparticles for mRNA-based cancer immunotherapy | |
Smyth Templeton | Cationic liposome-mediated gene delivery in vivo | |
US7384923B2 (en) | Liposomes | |
JP5977394B2 (ja) | 脂質に封入された干渉rna | |
US9737484B2 (en) | Amphoteric liposomes | |
JP4800485B2 (ja) | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 | |
Li et al. | Nonviral gene therapy | |
Smyth Templeton | Liposomal delivery of nucleic acids in vivo | |
US20060159737A1 (en) | Pharmaceutical compositions for local administration | |
US20060216343A1 (en) | Pharmaceutical compositions comprising an oligonucleotide as an active agent | |
JPH11512712A (ja) | 生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物 | |
Kimura et al. | Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization | |
JP4723097B2 (ja) | サイトフェクチン二量体およびその使用方法 | |
US7008791B1 (en) | Liposome-entrapped DNA oral vaccines | |
Sullivan | Non-Viral Gene Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041108 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100423 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100607 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100816 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100928 |